Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In recent years, patient research groups have spurred culture shifts in biomedical research and governance, with many health experts lauding the benefit of these groups’ being embedded in the research process. Some, however, question private-sector influence in these groups’ newfound power.
Melanoma Patient Network Europe has a lot of experience in connecting researchers with patients, including organizing patient-led conferences. The group’s founder explains how productive interaction can be transformative to research.
Patients with rare diseases, and the scientists who study those diseases, were long inhibited by geographic sparsity. But the social-media age has made it much easier for them to band together to leverage their experience and push forward change.
Patients’ contributions to biomedical research have quickly been shifting from passive participant to active contributor. But what happens when the person with lived experience of the disease becomes the clinical researcher?
The Human Cell Atlas has been undergoing a massive effort to support global scientific equity. The co-leaders of its Equity Working Group share some lessons learned in the process.
Anti-SARS-CoV-2 vaccines are being developed at an unprecedented pace, but what will the final vaccine or vaccines look like at approval and beyond? We asked six experts in vaccine development for their thoughts.
Delivering the potential of artificial intelligence in clinical decision-making will require testing interventions in well-designed randomized clinical trials and reporting these results in a standardized and transparent fashion.
With only a limited number of clinical trials of artificial intelligence in medicine thus far, the first guidelines for protocols and reporting arrive at an opportune time. Better protocol design, along with consistent and complete data presentation, will greatly facilitate interpretation and validation of these trials, and will help the field to move forward.